To validate the specificity of HMGN1 susceptibility to P2RY8::CRLF2, this study could be repeated to model another gene fusion with the same approach, such as ETV6::RUNX1 which is present in ~10% of DS–ALL patients (38). This evidence concerns the gene CRLF2 and acute lymphoblastic leukemia.